Influence of immunotropic drugs on immune parameters of patients with dry form of age-related macular degeneration
A. Petrunya, O. Yevsyukova
State Institution «Lugansk State Medical University»; Lugansk (Ukraine)
Background: AMD is a common cause of irreversible blindness in the elderly and has a high prevalence and a tendency to progressing.
Materials and methods: There were studied disturbance of cellular immunity in 78 patients with the dry form of age-related macular degeneration.
Results: The positive effect of the treatment on the cellular level of systemic immunity. After treatment, the concentration of IL-lα, IL-lβ, and NTF-α decreased to 18.3 %, 29.6 % and 36.9 % respectively, while IL-4 levels increased by 63.7 %, the concentration of TGF- β before the treatment was higher by 57.2 %; after treatment, the concentration of TGF-β decreased by 24 %.
Conclusion: It was established that the use of immunotropic drugs in patients with AMD helped normalize cellular immunity, which was not observed in the control group as well as to reduce the content and IgA TGF-β, normalization of the normal ratio of pro- and anti-inflammatory cytokines in the lachrymal fluid.
Key words: age-related macular degeneration (AMD), cellular immunity, local immunity, immune preparations.
1.Astakhov YuS, Lisochkina AB, Shadrichev FE. Age-related macular degeneration. Ophthalmology; national guidance. Avetisov SE, Moshetova LK, Neroev VV, Takhchidi KhP. Editors. M.:GEOTAR-Media; 2008.
2.Belenichev IF, Cherny VI, Kolesnik YuM, Pavlov SV. Rational neuroprotection. 2009. 262 p.
3.Boiko EV, Zhuravleva LV. Experience of using «Lutein forte» in the treatment of «dry» form of age-related macular degeneration. Klinicheskaia oftalmologiia. 2007;8(2).
4.Vervelskaia VM, Lebenkova OA. Features of frequency-critical and frequency-contrast sensitivity of the eye to the colors in optic atrophy. Akyualnyie voprosy sotsialnoi oftalmologii. 1988;2:43–47. In Russian.
5.Golubtsov KV, Kheilo TS, Shigina NA, Trunov VG, Aidu EA-I, Bykova TA, et al. The flickering light in the diagnosis and treatment of pathological processes of the human visual system. Informatsionnyie protsessy. 3(2):114–22. In Russian.
6.Granstrem OK et al. Cortexin: neuroprotection at the molecular level. Neiroimmunologiia. 2010;8(1–2):34–40. In Russian.
7.Egorova TE. Antioxidants in the treatment and prevention of the dry form of age-related macular degeneration. Literature review. Klin. Oftalmologiia. 2010;11(2):69–71. In Russian.
8.Zhuravleva LV, Churilova IV. The effectiveness of antioxidants in complex treatment of patients with age macular degeneration. Proceedings of VII Congress of ophthalmologists of Russia. M.;2000. 311. In Russian.
9.Libman ES, Shakhova EV. Blindness, visual impairment and visual disability in the Russian Federation. Proceedings of Russian interregional symposium. Ufa, 2003. 38–42. In Russian.
10.Libman ES, Shakhova EV. Blindness and disability due to pathology of the vision in Russia. Vestn Oftalmol. 2006;1:35–7. In Russian.
11.Maichuk YuF. The principles of the WHO global initiative to eliminate avoidable blindness. Their possible use in the Russian Federation. Okulist. 2003;44(4):5–8. In Russian.
12.Mukhina MA, Sotnikova EV, Kutepova OM. Social significance and urgency of treatment of age-related macular degeneration.. Proceedings of VII Congress of ophthalmologists of Russia. M.; 2000. 220. In Russian.
13.Pasyechnikova NV, Korol AR. Clinical classification and tactics of management of patients with age related macular degeneration. Oftalmol Zh. 2010;2:38–41. In Russian.
14.Ponomarchuk VS, Ivanov VA, Fiadoer S. Method and device for the differential diagnosis of pathological conditions of the retina. Oftalmol Zh. 1990;8:451–5. In Russian.
15.Tovkach VI. Photostress by conventional electric ophthalmoscope in the diagnosis of eye diseases. Voien. Med. Zhurnal. 1977;8:40–4. In Russian.
16.Frolov VM, Gaidash IS, Peresadin NA. Monoclonal antibodies in the study of cellular immunity. Laboratornoie delo. 1989;6:71–2. In Russian.
17.С De Palma et al. Endothelial nitric oxide synthase activation by tumor necrosis factor-a. Arterisclerosis, Throbbosis and vase. Biol. 2006;1:99–106.
18.Friedman E et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology. 1995; 102(4): 640- 6.
19.Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am. J. Ophthalmol. 2000;130(5):658–63.
20.Klein R, Klein BE, Knudtson MD et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006;113:373–80.
21.Pierce EA. Prophylactic treatment of drusen in AMD. Bio Essay. 2001; 23: 605–18.
22.Resnikoff S et al. Bulletin of the World Health Organization. 2004;82(11):844–51.
23.Williamson TH, Harris A. Color Doppler ultrasound imaging of the eye and orbit. Surv. Ophthalmol.1996; 40:255(203.)
24.Wu G, Weiter JJ, Santos S et al. The macular photostress test indiabetic retinopathy and age-related macular degeneration. Arch.Ophthalmol. 1990;108:1556–8.